Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer

被引:0
|
作者
Stabuc, B [1 ]
Markovic, A [1 ]
Plesnicar, A [1 ]
Cizej, TE [1 ]
机构
[1] Inst Oncol, Dept Med Oncol, Ljubljana 1000, Slovenia
关键词
colorectal cancer; 5-fluorouracil; methotrexate; biochemical modulation;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A phase II study was carried out to evaluate the efficacy and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and leucovorin (LV) in patients with advanced unresectable colorectal cancer. Forty-two patients with measurable metastases of colorectal cancer were treated with 5-FU in daily doses of 600 mg/m(2) given in a 6-hour intravenous (i.v.) infusion on days 1-5, LV 50 mg/m(2) i.v. on days 2,3 and 5, and MTX 40 mg/m(2) i.v on days 1 and 4, every 4 weeks. Twenty-eight patients had a single metastatic site, eleven double, whereas three had more than two metastatic sites. Objective response (one complete response) was observed in 12 of 40 patients (30%) (95% confidence interval 16-48), stable disease in 19 patients (47%) and progression in 9 patients (23%). Overall median survival was 12 months. Median time to progression was 6 months. Treatment was generally well tolerated. The most frequent adverse reactions were stomatitis (38%), nausea and vomiting (35%), diarrhea (31%), leukopenia (18%), and plantar-palmar erythroderma (15%). The combination of 5-FU, LV and MTX seems to be an active regimen in advanced colorectal cancer.
引用
收藏
页码:248 / 252
页数:5
相关论文
共 50 条
  • [31] 5-FLUOROURACIL MODULATION IN THE CHEMOTHERAPY OF COLORECTAL-CANCER
    CODACCIPISANELLI, G
    FRANCHI, F
    ITALIAN JOURNAL OF GASTROENTEROLOGY, 1994, 26 (07): : 369 - 376
  • [32] Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: A phase IB study
    Punt, CJA
    Kamm, YL
    Wagener, DJT
    ANTI-CANCER DRUGS, 1997, 8 (05) : 454 - 458
  • [33] Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil
    Shimada, S
    Yagi, Y
    Shiomori, K
    Kuramoto, M
    Aoki, N
    Ogawa, M
    ONCOLOGY REPORTS, 2002, 9 (04) : 783 - 787
  • [34] EFFECT OF CISPLATIN IN ADVANCED COLORECTAL-CANCER RESISTANT TO 5-FLUOROURACIL PLUS (S)-LEUCOVORIN
    CASSANO, A
    POZZO, C
    CORSI, CD
    FONTANA, T
    NOVIELLO, MR
    ASTONE, A
    BARONE, C
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1995, 121 (08) : 474 - 477
  • [35] Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study
    Alfredo Falcone
    Giacomo Allegrini
    Monica Lencioni
    Elisabetta Pfanner
    Isa Brunetti
    Caudia Cianci
    Costanza Galli
    Gianluca Masi
    Andrea Antonuzzo
    Pierfranco Conte
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 159 - 163
  • [36] Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer:: final results of a randomised European study
    Punt, CJA
    Keizer, HJ
    Douma, J
    Skovsgaard, T
    Schüller, J
    Muller, EW
    Ten Napel, CHH
    Croles, JJ
    Lochs, H
    Zhang, J
    Hammershaimb, L
    ANNALS OF ONCOLOGY, 2002, 13 (01) : 81 - 86
  • [37] PREOPERATIVE 5-FLUOROURACIL, LOW-DOSE LEUCOVORIN, AND CONCURRENT RADIATION-THERAPY FOR RECTAL-CANCER
    MINSKY, B
    COHEN, A
    ENKER, W
    KELSEN, D
    KEMENY, N
    ILSON, D
    GUILLEM, J
    SALTZ, L
    FRANKEL, J
    CONTI, J
    CANCER, 1994, 73 (02) : 273 - 280
  • [38] Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil
    A Guglielmi
    S Barni
    A Zaniboni
    N Pella
    O Belvedere
    G D Beretta
    F Grossi
    L Frontini
    F Puglisi
    R Labianca
    A Sobrero
    British Journal of Cancer, 2004, 91 : 1428 - 1433
  • [39] Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)
    Kouroussis, C
    Souglakos, J
    Mavroudis, D
    Papadouris, S
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Panopoulos, C
    Vardakis, N
    Sarra, E
    Georgoulias, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 627 - 631
  • [40] Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil
    Guglielmi, A
    Barni, S
    Zaniboni, A
    Pella, N
    Belvedere, O
    Beretta, GD
    Grossi, F
    Frontini, L
    Puglisi, F
    Labianca, R
    Sobrero, A
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1428 - 1433